Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Long-term Open-label Study of DE-117 Ophthalmic Solution Monotherapy and Concomitant Use of DE-117 Ophthalmic Solution With Timolol Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension : RENGE Study

Trial Profile

A Long-term Open-label Study of DE-117 Ophthalmic Solution Monotherapy and Concomitant Use of DE-117 Ophthalmic Solution With Timolol Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension : RENGE Study

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 12 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Omidenepag isopropyl (Primary) ; Timolol
  • Indications Exfoliation syndrome; Ocular hypertension; Open-angle glaucoma; Pigmentary glaucoma
  • Focus Adverse reactions; Registrational
  • Acronyms RENGE
  • Sponsors Santen Pharmaceutical
  • Most Recent Events

    • 01 Nov 2021 Primary endpoint (Change and percent change from baseline in mean diurnal IOP and mean IOP at each scheduled timepoint) has been met as per results published in the Japanese Journal of Ophthalmology
    • 01 Nov 2021 Results published in the Japanese Journal of Ophthalmology
    • 16 Nov 2017 Status changed from recruiting to completed.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top